Version 3.2.0 of the TMF Reference Model Launched
The TMF Reference Model Steering Committee announced that version 3.2.0 of the Trial Master File Reference Model is now available to download free of charge. This latest release incorporates updates developed in response to 25 requests from industry received through June 2020. As a result, Version 3.2.0 of the Reference Model reflects updated regulatory guidance and current industry best practices.
“This latest version of the TMF Reference Model builds on the hard work and incredible collaboration of so many people in our industry to standardize and simplify TMF management processes,” said Karen Roy, Chair of the TMF Reference Model Steering Committee. “In the 10 years since version 1.0 of the TMF Reference Model was launched, we have seen it embraced by organizations worldwide as a critical component supporting Trial Master File compliance and inspection-readiness. We fully expect version 3.2.0 to be a valuable contribution to this ongoing effort.”
To learn more, click here.
The Importance of Real-World Evidence in Medical Research and Drug Development
February 18th 2025The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its growing importance and vast potential to improve personalized medicine, overall healthcare outcomes, and eventually democratization of scientific facts by general accessibility.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
